Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT00328042 Completed - Hepatitis C Clinical Trials

Hepatitis C Self-Management

Start date: May 2007
Phase: N/A
Study type: Interventional

The objective of this study is to compare the efficacy of a 6-session hepatitis C self-management workshop to a hepatitis C self-management self-study program. Both interventions are designed to help people with hepatitis C learn to actively self-manage their chronic HCV infection, and ultimately, to improve health outcomes for veterans with HCV who are not receiving Interferon-based treatment. Participants complete a total of four assessments. The fourth assessment, a 12-18 month assessment is an approved addition to the original study design

NCT ID: NCT00325611 Completed - Stroke Clinical Trials

Multidisciplinary Inpatient Palliative Care Intervention

Start date: April 2002
Phase: N/A
Study type: Interventional

Palliative care is believed to improve care of patients with life-limiting illnesses. This study evaluated the impact of a multi-center randomized trial of a palliative care team intervention on the quality and cost of care of hospitalized patients. Study subjects were randomized to intervention or usual care. At study end, patients receiving the palliative care intervention reported greater patient satisfaction with their care. Intervention patients also had significantly fewer ICU admissions and lower total costs for care 6 months past their hospitalization. Intervention patients completed more advance directives and had longer hospice stays.

NCT ID: NCT00325169 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

SERETIDE Plus Tiotropium Versus Individual Components

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the effects on lung function of a combination of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg once daily alone and SERETIDE 50/500mcg twice daily alone) in subjects with COPD. The study will utilise a three-way cross-over design with a 2-week wash-out period between each 2-week consecutive treatment period.

NCT ID: NCT00309296 Completed - Chronic Diseases Clinical Trials

Longitudinal Care: Smoking Reduction to Aid Cessation

Start date: November 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether an extended care treatment model lasting over a year will increase long-term smoking cessation rates compared to the standard 8 week treatment of care.

NCT ID: NCT00295113 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions

Start date: November 2001
Phase: N/A
Study type: Interventional

The aim of the study is to observe the ventilatory and cardiac function (included the pulmonary arterial pressure) during an intermittent work exercise test with high density work load.

NCT ID: NCT00292552 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

ECLIPSE
Start date: December 2005
Phase: N/A
Study type: Observational

This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.

NCT ID: NCT00292448 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in patients with COPD.

NCT ID: NCT00281567 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

Start date: August 2002
Phase: Phase 3
Study type: Interventional

Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.

NCT ID: NCT00281242 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Start date: September 2005
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether there is a statistical association between changes in sputum serial levels of two cytokines, interleukin (IL)-17 and IL-6, during the treatment course of a severe acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and during the clinical course itself (i.e., rate of recovery or potential complicated course). AE-COPD is defined as an episode requiring emergency room (ER) evaluation.

NCT ID: NCT00281229 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Start date: September 2005
Phase:
Study type: Observational

The purpose of this study is to determine whether the lungs of individuals with chronic obstructive pulmonary disease (COPD) contain resident memory T lymphocytes that can produce a combination of cytokines that induce the symptoms of an acute exacerbation of COPD (AE-COPD). Specifically, the study will determine cell-surface receptors of lung T cells in comparison with blood T cells from the same subject, and will examine anti-CD3-activated blood or lung T cells for interleukin (IL)-6 and interferon-gamma production in response to IL-18, and for IL-17A production in response to recombinant IL-23.